Tirzepatide Once Weekly for the Treatment of Obesity
Open accessThe DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Obesity is a chronic disease that results in substantial global morbidity and mortality. The efficacy and safety of tirzepatide, a novel glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonist, in people with obesity are not known. METHODS: In this phase 3 double-blind, randomized, controlled trial, we assigned 2539 adults with a body-mass index (BMI; the weight in kilograms divided by the square of the height in meters) of 30 or more, or 27 or more and at least one weight-related complication, excluding diabetes, in a 1:1:1:1 ratio to receive once-weekly, subcutaneous tirzepatide (5 mg, 10 mg, or 15 mg) or placebo for 72 weeks, including a 20-week dose-escalation period. Coprimary end points were the percentage change in weight from baseline and a weight reduction of 5% or more. The treatment-regimen estimand assessed effects regardless of treatment discontinuation in the intention-to-treat population. RESULTS: At baseline, the mean body weight was 104.8 kg, the mean BMI was 38.0, and 94.5% of participants had a BMI of 30 or higher. The mean percentage change in weight at week 72 was -15.0% (95% confidence interval [CI], -15.9 to -14.2) with 5-mg weekly doses of tirzepatide, -19.5% (95% CI, -20.4 to -18.5) with 10-mg doses, and -20.9% (95% CI, -21.8 to -19.9) with 15-mg doses and -3.1% (95% CI, -4.3 to -1.9) with placebo (P<0.001 for all comparisons with placebo). The percentage of participants who had weight reduction of 5% or more was 85% (95% CI, 82 to 89), 89% (95% CI, 86 to 92), and 91% (95% CI, 88 to 94) with 5 mg, 10 mg, and 15 mg of tirzepatide, respectively, and 35% (95% CI, 30 to 39) with placebo; 50% (95% CI, 46 to 54) and 57% (95% CI, 53 to 61) of participants in the 10-mg and 15-mg groups had a reduction in body weight of 20% or more, as compared with 3% (95% CI, 1 to 5) in the placebo group (P<0.001 for all comparisons with placebo). Improvements in all prespecified cardiometabolic measures were observed with tirzepatide. The most common adverse events with tirzepatide were gastrointestinal, and most were mild to moderate in severity, occurring primarily during dose escalation. Adverse events caused treatment discontinuation in 4.3%, 7.1%, 6.2%, and 2.6% of participants receiving 5-mg, 10-mg, and 15-mg tirzepatide doses and placebo, respectively. CONCLUSIONS: In this 72-week trial in participants with obesity, 5 mg, 10 mg, or 15 mg of tirzepatide once weekly provided substantial and sustained reductions in body weight. (Supported by Eli Lilly; SURMOUNT-1 ClinicalTrials.gov number, NCT04184622.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Many patients treated with GLP-1RAs achieve clinically meaningful weight loss while simultaneously demonstrating improvements in cardiometabolic health.45,46”
From Receipt of Glucagon-Like Peptide-1 Receptor Agonists Among Rural Patients with Obstructive Sleep Apnea and Excess Weight (2026) · cites this paper as [46]
In the citing paper
“with two articles presenting LM outcomes in only a subset of participants from the parent trial (6, 7).”
From G LP1Ra ‐based therapies and DXA ‐acquired musculoskeletal health outcomes: a focused meta‐analysis of placebo‐controlled trials (2025) · cites this paper as [7]
In the citing paper
“Indeed, clinical trials demonstrate substantial weight loss achievable with GLP1Ra-based therapy, ranging from 12-15% over a one-year period for semaglutide (6), to weight losses rivaling what is seen with bariatric surgery for tirzepatide (7).”
From G LP1Ra ‐based therapies and DXA ‐acquired musculoskeletal health outcomes: a focused meta‐analysis of placebo‐controlled trials (2025) · cites this paper as [7]
In the citing paper
“Across body weight and composition outcomes, the greatest magnitude of weight loss was observed in the SURMOUNT (7) and STEP (6) trials, respectively.”
From G LP1Ra ‐based therapies and DXA ‐acquired musculoskeletal health outcomes: a focused meta‐analysis of placebo‐controlled trials (2025) · cites this paper as [7]
In the citing paper
“However, the magnitude of the treatment effect on total body mass was nearly two times greater in trials using GLP1Ra-based therapies at dosages indicated primarily for chronic weight management (6, 7, 18, 21, 24) as compared to trials using dosages indicated primarily for diabetes management (17, 19, 20, 22): −10.2 kg (−16.3, −3.9) versus −5.5 kg (−8.7, −2.1), respectively.”
From G LP1Ra ‐based therapies and DXA ‐acquired musculoskeletal health outcomes: a focused meta‐analysis of placebo‐controlled trials (2025) · cites this paper as [7]
174 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Once-Weekly Semaglutide in Adults with Overweight or Obesity
Wilding, J. P. H., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., McGowan, B. M., Rosenstock, J., Tran, M. T. D., Wadden, T. A., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2032183 · Cited by 5,205
Self-citationObesity and cardiovascular disease: a scientific statement from the American Heart Association
Powell-Wiley, T. M., Poirier, P., Burke, L. E., Després, J.-P., Gordon-Larsen, P., Lavie, C. J., Lear, S. A., Ndumele, C. E., Neeland, I. J., Sanders, P., et al. (2021) · Circulation · doi:10.1161/cir.0000000000000973 · Cited by 3,691
Di Angelantonio, E., Bhupathiraju, S. N., Wormser, D., Gao, P., Kaptoge, S., de Gonzalez, A. B., Cairns, B. J., Huxley, R., Jackson, C. L., Joshy, G., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)30175-1 · Cited by 2,821
A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management
Pi-Sunyer, X., Astrup, A., Fujioka, K., Greenway, F., Halpern, A., Krempf, M., Lau, D. C. W., le Roux, C. W., Violante Ortiz, R., Jensen, C. B., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1411892 · Cited by 2,724
2. Classification and Diagnosis of Diabetes:Standards of Medical Care in Diabetes—2019
American Diabetes Association (2019) · Diabetes Care · doi:10.2337/dc19-s002 · Cited by 2,697
Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes
Frías, J. P., Davies, M. J., Rosenstock, J., Pérez Manghi, F. C., Fernández Landó, L., Bergman, B. K., Liu, B., Cui, X., & Brown, K. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2107519 · Cited by 2,096
Self-citationGarvey, W. T., Mechanick, J. I., Brett, E. M., Garber, A. J., Hurley, D. L., Jastreboff, A. M., Nadolsky, K., Pessah-Pollack, R., & Plodkowski, R. (2016) · Endocrine Practice · doi:10.4158/ep161365.gl · Cited by 1,914
Self-citationObesity in adults: a clinical practice guideline
Wharton, S., Lau, D. C. W., Vallis, M., Sharma, A. M., Biertho, L., Campbell-Scherer, D., Adamo, K., Alberga, A., Bell, R., Boulé, N., et al. (2020) · Canadian Medical Association Journal · doi:10.1503/cmaj.191707 · Cited by 1,506
Self-citationRubino, D., Abrahamsson, N., Davies, M., Hesse, D., Greenway, F. L., Jensen, C., Lingvay, I., Mosenzon, O., Rosenstock, J., Rubio, M. A., et al. (2021) · JAMA · doi:10.1001/jama.2021.3224 · Cited by 1,444
Davies, M., Færch, L., Jeppesen, O. K., Pakseresht, A., Pedersen, S. D., Perreault, L., Rosenstock, J., Shimomura, I., Viljoen, A., Wadden, T. A., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00213-0 · Cited by 1,419
Cited by
Items 901–1,000 of 3,704
Espinel, E., Azancot, M. A., Gómez, A., Beneria, A., Caraben, A., Andurell, L., Delgado, P., Castañé, H., Joven, J., & Serón, D. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12020679 · Cited by 18
“Likewise, because drugs with modest weight-reducing effects decrease BP in patients with hypertension [18], novel and highly effective agents for weight loss in patients with obesity may result in substantial improvement [19].”
BackgroundA year in pharmacology: new drugs approved by the US Food and Drug Administration in 2022
Kayki‐Mutlu, G., Aksoyalp, Z. Ş., Wojnowski, L., & Michel, M. C. (2023) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-023-02465-x · Cited by 18
Clinical evaluation of patients living with obesity
Dobbie, L. J., Matta-Coelho, C., Crane, J. D., & McGowan, B. M. (2023) · Internal and Emergency Medicine · doi:10.1007/s11739-023-03263-2 · Cited by 25
Perspectives on weight control in diabetes – Tirzepatide
Várkonyi, T. T., Pósa, A., Pávó, N., & Pavo, I. J. (2023) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2023.110770 · Cited by 23
“In these individuals, the weight reduction with tirzepatide was larger than that of the patients with T2D in the SURPASS program [65].”
ResultCagriSema and the link between obesity and type 2 diabetes
Apovian, C. M., & McDonnell, M. E. (2023) · The Lancet · doi:10.1016/s0140-6736(23)01291-6 · Cited by 15
Lyons, S. A., & Beaudry, J. L. (2023) · Endocrinology · doi:10.1210/endocr/bqad153 · Cited by 19
Challenging Clinical Perspectives in Type 2 Diabetes with Tirzepatide, a First-in-Class Twincretin
MacIsaac, R. J., Deed, G., dʼEmden, M. C., Ekinci, E. I., HOCKING, S. L., Sumithran, P., & Rasalam, R. R. (2023) · Diabetes Therapy · doi:10.1007/s13300-023-01475-5 · Cited by 17
“Notably, 57% of participants receiving tirzepa-tide 10 or 15 mg achieved weight loss of 20% or more [52].”
BackgroundBrennan, P., Zelber‐Sagi, S., Allen, A. M., Dillon, J. F., & Lazarus, J. V. (2023) · Gut · doi:10.1136/gutjnl-2023-330771 · Cited by 18
“30 31 However, challenges remain regarding the cost, long-term safety and accessibility of such weight management medications.”
BackgroundMuzurović, E. M., Yumuk, V., & Rizzo, M. (2023) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2023.108647 · Cited by 15
Poly-Agonist Pharmacotherapies for Metabolic Diseases: Hopes and New Challenges
Allard, C., Cota, D., & Quarta, C. (2023) · Drugs · doi:10.1007/s40265-023-01982-6 · Cited by 17
“…of tirzepatide achieving − 20.9% and − 14.7% weight loss, respectively, making it the most effective drug so far generated against body weight loss [165] (Lilly press release https:// inves tor. lilly. com/ news-relea ses/ news-relea se-detai ls/ lillys-tirze patide-achie ved- 157- weight- loss-…”
InfluentialPharmacological interventions in human aging
Petr, M. A., Matiyevskaya, F., Osborne, B., Berglind, M., Reves, S., Zhang, B., Ezra, M. B., Carmona-Marin, L. M., Syadzha, M. F., Mediavilla, M. C., et al. (2024) · Ageing Research Reviews · doi:10.1016/j.arr.2024.102213 · Cited by 22
Incretin and glucagon receptor polypharmacology in chronic kidney disease
McFarlin, B. E., Duffin, K. L., & Konkar, A. A. (2024) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00374.2023 · Cited by 17
McGill, J. B., Hirsch, I. B., Parkin, C. G., Aleppo, G., Levy, C. J., & Gavin, J. R. (2024) · Diabetes Therapy · doi:10.1007/s13300-024-01569-8 · Cited by 29
“As demonstrated in numerous studies [5, 26–34, 90 In this article we have reviewed the benefits and potential adverse consequences associated with GLP-1 RA therapy relevant to discontinuation of therapy, which is often due to intolerable GI side effects.”
BackgroundResultInfluentialSarzani, R., Landolfo, M., Pentima, C. D., Ortensi, B., Falcioni, P., Sabbatini, L., Massacesi, A., Rampino, I., Spannella, F., & Giulietti, F. (2024) · Frontiers in Medicine · doi:10.3389/fmed.2024.1365183 · Cited by 26
Treating obesity and fertility in the era of glucagon-like peptide 1 receptor agonists
Goldberg, A. S., & Boots, C. E. (2024) · Fertility and Sterility · doi:10.1016/j.fertnstert.2024.05.154 · Cited by 24
Anti-atherosclerotic effect of incretin receptor agonists
Wang, X., Yang, X., Qi, X., Fan, G., Zhou, L., Peng, Z., & Yang, J. (2024) · Frontiers in Endocrinology · doi:10.3389/fendo.2024.1463547 · Cited by 22
Jirapinyo, P., Jaroenlapnopparat, A., & Thompson, C. C. (2024) · Endoscopy International Open · doi:10.1055/a-2463-9784 · Cited by 17
Douros, J. D., Flak, J. N., & Knerr, P. J. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1530985 · Cited by 18
Towards a phenotype profiling of the patients with heart failure and preserved ejection fraction
Bonfioli, G. B., Pagnesi, M., Calò, L., & Metra, M. (2025) · European Heart Journal Supplements · doi:10.1093/eurheartjsupp/suae095 · Cited by 20
“24 The SUMMIT trial (NCT04847557) will provide insights on the effects of tirzepatide compared with placebo in obese patients with HFpEF.”
Sex Differences in Obesity and Its Treatment
Ghanta, A., Wilson, E., & Chao, A. M. (2025) · Current Psychiatry Reports · doi:10.1007/s11920-025-01601-z · Cited by 20
“…has been revolutionized by the introduction of the highly effective second-generation anti-obesity medications (AOMs), semaglutide and tirzepatide, which are incretin-based medications that produced average losses of > 10% of initial body weight with accompanying health improvements [ 8 , 9].”
InfluentialReytor-González, C., Annunziata, G., Campuzano-Donoso, M., Morales-López, T., Basantes-Tituaña, C., Fascì-Spurio, F., Verde, L., Muscogiuri, G., Barrea, L., Frías-Toral, E., et al. (2025) · Minerva Endocrinology · doi:10.23736/s2724-6507.24.04314-8 · Cited by 25
Sawami, K., Tanaka, A., & Node, K. (2022) · Cardiovascular Diabetology · doi:10.1186/s12933-022-01611-8 · Cited by 15
“9% from baseline compared with placebo in the SURMOUNT-1 trial [15].”
ResultChakhtoura, M., & Mantzoros, C. S. (2023) · Metabolism · doi:10.1016/j.metabol.2023.155531 · Cited by 16
Fitch, A., Gigliotti, L., & Bays, H. E. (2025) · Obesity Pillars · doi:10.1016/j.obpill.2025.100205 · Cited by 14
“…obesity and without diabetes, percentage weight reduction from baseline was 20.9 % with tirzepatide (15 mg once weekly) after 72 weeks of treatment [40], 14.9 % with semaglutide (2.4 mg once weekly) after 68 weeks of treatment [41], and 8.0 % with liraglutide (3.0 mg once daily) after 56 weeks of…”
InfluentialMcKenzie, A. L., & Athinarayanan, S. J. (2024) · Diabetes Therapy · doi:10.1007/s13300-024-01547-0 · Cited by 14
“Recent pharmaceutical advancements among incretin mimetics like GLP-1 show great potential, having elicited substantial glucose-lowering effects in T2D [9–16] and weight loss nearing that which is achieved through surgical intervention among people with excess weight or obesity without T2D [17, 18].”
BackgroundIppolito, B., & Levy, J. F. (2024) · Health Affairs · doi:10.1377/hlthaff.2024.00356 · Cited by 14
Hawkins, L. K., Burns, L., Swancutt, D. R., Moghadam, S., Pinkney, J. H., Tarrant, M., & The PROGROUP Programme Team (2024) · Obesity Reviews · doi:10.1111/obr.13798 · Cited by 19
“7 Pharmacological interventions are another treatment option for some people, with a new generation of drugs proving able to support significant weight loss (e.g., Semaglutide 8 and Tirzepatide 9 ) in the short term; long-term effects, including side effects, remain to be seen.”
Forst, T. M., Block, C. E. M. D., Prato, S. D., Frías, J. P., Lautenbach, A., Ludvik, B. H., Marinez, M., Mathieu, C., Müller, T. D., & Schnell, O. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16247 · Cited by 15
“119,123,124,126 The SYNERGY-NASH trial is a phase 2 study investigating the effect of tirzepatide over 52 weeks on MASH progression in 157 patients with biopsy-confirmed MASH and stage F2 or F3 fibrosis.”
InfluentialGagner, M., Abuladze, D., Buchwald, J. N., Koiava, L., & Almutlaq, L. (2025) · Journal of the American College of Surgeons · doi:10.1097/xcs.0000000000001384 · Cited by 15
“49,50 Also, over the short term, a meta-analysis of 7 GLP-1 agents studied in 27 randomized controlled trials (15,584), found GLP-1 agents significantly less effective in patients with T2D.”
Physiology and clinical applications of GIP
Yamane, S., Harada, N., & Inagaki, N. (2025) · Endocrine Journal · doi:10.1507/endocrj.ej25-0087 · Cited by 16
“In the SURMOUNT-1 and SURMOUNT-3 trials, a high dose of tirzepatide (15 mg), administered subcutaneously once a week, led to approximately a 20% reduction in body weight among non-diabetic adults with a BMI ≥27 kg/m 2 after two years of treatment [142, 143].”
Christensen, S. M., & Nelson, C. (2025) · Obesity Pillars · doi:10.1016/j.obpill.2025.100175 · Cited by 21
“Similarly, in the Study of Tirzepatide in Participants with Obesity or Overweight (SURMOUNT-1) trial, 10.9 % of lean muscle mass was lost during the treatment period in the patients analyzed [74].”
InfluentialA combinatorial siRNA and mRNA approach for obesity treatment using targeting lipid nanoparticles
Stewart, W., Hu, B., Li, F., Huang, J., Liu, Z., Zhang, C., Tang, M., Zhang, X., & Xu, X. (2025) · Journal of Controlled Release · doi:10.1016/j.jconrel.2025.113857 · Cited by 19
Incretin Receptor Agonism, Fat-free Mass, and Cardiorespiratory Fitness: A Narrative Review
Liu, Z., Weeldreyer, N. R., & Angadi, S. S. (2025) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaf335 · Cited by 21
Adekunle, O. A., Le, P. N. B., Gupta, D. Y., Rothberg, M. B., Tran, H. T., Yue, Y., & Gasoyan, H. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16544 · Cited by 13
Malhotra, A., Grunstein, R. R., Azarbarzin, A., Sands, S. A., Dang, X., Chakladar, S., Dunn, J. P., Falcón, B. L., & Bednařík, J. (2025) · Sleep Medicine · doi:10.1016/j.sleep.2025.106853 · Cited by 23
Velji-Ibrahim, J., Radadiya, D. K., Devani, K., Patel, H. K., Nathani, P., Hassan, C., Pugliese, N., Thompson, C., & Sharma, P. (2025) · Journal of Obesity · doi:10.1155/jobe/3897161 · Cited by 23
Viana, D. P. D. C., Invitti, A. L., & Schor, E. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms262110741 · Cited by 21
Buonanno, S., Gaggiano, C., Terribili, R., Cantarini, L., Frediani, B., & Gentileschi, S. (2025) · Inflammation Research · doi:10.1007/s00011-025-02140-2 · Cited by 23
GLP-1 receptor agonists for obesity: eligibility across 99 countries
Yoo, S. G. K., Teufel, F., Theilmann, M., Si, Y., Touré, E. A., Aryal, K. K., Bärnighausen, T., Bait, A., Barreto, M., Bovet, P., et al. (2026) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(25)00356-0 · Cited by 24
Bays, H. E., Toth, P. D., Alkhouri, N., Pullman, J. R., Freilich, B., Neutel, J., Ji, S., Stubbe, S., Hedges, P., & Lian, B. (2026) · Obesity · doi:10.1002/oby.70106 · Cited by 16
“While the TEAE profile was similar to semaglutide and tirzepatide in that GI TEAEs were most common [20, 23], few long-term GI TEAEs were observed.”
InfluentialRazzaki, T. S., Weiner, A., & Shukla, A. P. (2022) · Therapeutics and Clinical Risk Management · doi:10.2147/tcrm.s328056 · Cited by 16
“This will evaluate the progression to T2DM at three years of treatment with tirzepatide compared to placebo.(31)”
Theofilis, P., Vordoni, A., & Kalaitzidis, R. (2022) · Life · doi:10.3390/life12101663 · Cited by 15
Utility of Hypoglycemic Agents to Treat Asthma with Comorbid Obesity
Ge, D., Foer, D., & Cahill, K. N. (2022) · Pulmonary Therapy · doi:10.1007/s41030-022-00211-x · Cited by 14
“Two recent phase 3 multicenter randomized trials in adults with obesity showed that tirzepatide, a novel dual gastric inhibitory peptide\GLP-1R agonist, caused substantial weight loss in patients who failed to lose weight via dietary changes and noninferior and superior glycemic control compared to semaglutide in thos…”
BackgroundAdolescents with Type 2 Diabetes: Overcoming Barriers to Effective Weight Management
Salama, M., Biggs, B. K., Creo, A. L., Prissel, R., Nofal, A. A., & Kumar, S. (2023) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s365829 · Cited by 17
Tirzepatide and potential use for metabolically healthy obesity
Çöpür, S., Tanrıöver, C., Yavuz, F., Tuttle, K. R., & Kanbay, M. (2023) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2023.05.012 · Cited by 18
Burkett, W. C., Clontz, A. D., Keku, T. O., & Bae-Jump, V. L. (2023) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2023.189000 · Cited by 24
Padiadpu, J., García‐Jaramillo, M., Newman, N. K., Pederson, J. W., Rodrigues, R. R., Li, Z., Singh, S. P., Monnier, P., Trinchieri, G., Brown, K., et al. (2023) · EMBO Molecular Medicine · doi:10.15252/emmm.202318367 · Cited by 14
“For many metabolic diseases such as diabetes (Jermendy et al , 2018; Dahl (cid:1) en et al , 2021), atherosclerosis (Bhatt et al , 2019), and obesity (Jastreboff et al , 2022) there are highly efficient drugs that treat and/or prevent development of these diseases.”
BackgroundGIPR Agonism Enhances TZD-Induced Insulin Sensitivity in Obese IR Mice
Furber, E. C., Hyatt, K., Collins, K. A. L., Yu, X., Droz, B. A., Holland, A. K., Friedrich, J. L., Wojnicki, S., Konkol, D. L., O’Farrell, L. S., et al. (2023) · Diabetes · doi:10.2337/db23-0172 · Cited by 17
Antiobesity pharmacotherapy to facilitate living kidney donation
Orandi, B. J., Lofton, H. F., Montgomery, R. A., & Segev, D. L. (2023) · American Journal of Transplantation · doi:10.1016/j.ajt.2023.12.003 · Cited by 16
Treat Obesity to Treat Type 2 Diabetes Mellitus
Sulu, C., & Yumuk, V. (2024) · Diabetes Therapy · doi:10.1007/s13300-024-01536-3 · Cited by 24
“Studies have reported that treatment with exenatide, liraglutide, semaglutide or tirzepatide offer a significantly reduced risk of T2DM compared to placebo [32–37].”
BackgroundVajravelu, M. E., Chu, P. Y., Frank, D. A., Ragavan, M. I., & Vajravelu, R. K. (2024) · Pediatric Obesity · doi:10.1111/ijpo.13103 · Cited by 14
“15 Additionally, we did not account for pre-existing conditions that may preclude use of anti-obesity pharmacotherapy.”
BackgroundMoreno, Ó., Reyes‐García, R., Pardo, I. M., López-Martínez, M., & Soler, M. J. (2024) · Clinical Kidney Journal · doi:10.1093/ckj/sfae039 · Cited by 15
“Finally, retatrutide ( a novel single peptide derived from the GIP peptide backbone with agonist activity at GIPR, GLP1R and GCGR) achieved a WL of − 17% in PWT2D and 24% in people with obesity in phase 2 studies [84 , 85 ].”
BackgroundGLP1-GIP receptor co-agonists: a promising evolution in the treatment of type 2 diabetes
Ciardullo, S., Morieri, M. L., DANIELE, G., Fiorentino, T. V., Mezza, T., Tricò, D., Consoli, A., Prato, S. D., Giorgino, F., Piro, S., et al. (2024) · Acta Diabetologica · doi:10.1007/s00592-024-02300-6 · Cited by 19
Obesity treatment in adolescents and adults in the era of personalized medicine
Sundbom, M., Järvholm, K., Sjögren, L., Nowicka, P., & Lagerros, Y. T. (2024) · Journal of Internal Medicine · doi:10.1111/joim.13816 · Cited by 18
“Weekly injections of tirzepatide resulted in a 20.9% weight reduction compared to 3.2% for the placebo group after 72 weeks [35].”
InfluentialYuan, J., Liu, W., Jiang, X., Huang, Y., Zong, L., Ding, H., Shen, X., Sun, Y., Feng, X., Li, X., et al. (2024) · Scientific Reports · doi:10.1038/s41598-024-66998-8 · Cited by 19
Chronic obstructive pulmonary disease and obstructive sleep apnea overlap: who to treat and how?
Sunwoo, B. Y., Raphelson, J. R., & Malhotra, A. (2024) · Expert Review of Respiratory Medicine · doi:10.1080/17476348.2024.2384036 · Cited by 20
Tirzepatide-Induced Rapid Weight Loss–Related Thyrotoxicosis
Karakus, K. E., Shah, V. N., & Aktürk, H. K. (2024) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2024.2919 · Cited by 16
Guccio, N., Alcaino, C., Miedzybrodzka, E. L., Santos-Hernández, M., Smith, C. A., Davison, A., Bakar, R. B., Kay, R. G., Reimann, F., & Gribble, F. M. (2024) · Diabetologia · doi:10.1007/s00125-024-06293-3 · Cited by 19
Boccardi, V., Bahat, G., Balcı, C., Bourdel‐Marchasson, I., Christiaens, A., Donini, L. M., Çavdar, S., Maggi, S., Özkök, S., Pavić, T., et al. (2025) · European Geriatric Medicine · doi:10.1007/s41999-025-01168-1 · Cited by 21
“Recent clinical trials have demonstrated its superior efficacy on glycaemic control and weight management compared to traditional GLP-1 RA, marking it as a key development in diabetes care [59, 60].”
Petersen, J., Merrild, C., Lund, J., Holm, S., & Clemmensen, C. (2024) · Molecular Metabolism · doi:10.1016/j.molmet.2024.102027 · Cited by 13
“Incretin hormone-based weight loss therapies, such as semaglutide and tirzepatide, reduce body weight by 15 e 20% in clinical trials involving individuals with obesity [20,33].”
InfluentialJakicic, J. M., Behrens, C. E., Deemer, S. E., Forseth, B., Katsanos, C. S., Nickerson, B. S., Prado, W. L., Wang, X., Deru, L. S., & Rogers, R. J. (2026) · Journal of Sport and Health Science · doi:10.1016/j.jshs.2025.101097 · Cited by 13
“15,16 While these OMMs are effective for weight loss, there has been some concern that the weight loss is accompanied by excessive loss of lean mass. 17 To date, there are no published studies that have reported on the effects of adding exercise at the onset of treatment using an OMM and,…”
Wong, S. W., Yang, Y., Chen, H., Xie, L. H., Shen, X., Zhang, N., & Wu, J. H. (2025) · Acta Pharmacologica Sinica · doi:10.1038/s41401-024-01466-7 · Cited by 14
Glycemic Targets and Prevention of Complications
Tsushima, Y., & Galloway, N. (2025) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgae776 · Cited by 21
Elhag, W., & Ansari, W. E. (2025) · Obesity Surgery · doi:10.1007/s11695-024-07654-y · Cited by 15
“With the approval of many new anti-obesity medications [91, 92], future physicians require solid education on their indications, effectiveness, dosage, side effects, and safety [93].”
Recent advances in targeting obesity, with a focus on TGF-β signaling and vagus nerve innervation
John, S., Bhowmick, K., Park, A., Huang, H., Yang, X., & Mishra, L. (2025) · Bioelectronic Medicine · doi:10.1186/s42234-025-00172-x · Cited by 15
“Glucagon-like peptide 1 (GLP-1) receptor agonist (GLP-1 RA) Semaglutide and Tirzepatide, dual GIP/GLP-1 receptor agonists, have shown significant efficacy in reducing body weight and improving glucose control (Jastreboff et al. 2022; Wilding et al. 2021).”
Zamanian, N., Imani, H., Talebi, S., Rahimlou, M., Khosroshahi, R. A., & Mohammadi, H. (2025) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2025.177966 · Cited by 19
Zheng, W., Qi, Q., Li, J., He, C., & Fan, H. (2025) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-025-01917-z · Cited by 19
Reitz, J., Rosoff, D. B., Perlstein, T., Wagner, A., Jung, J., Wagner, J., Reiner, B. C., & Lohoff, F. W. (2025) · Molecular Psychiatry · doi:10.1038/s41380-025-03199-3 · Cited by 18
“May-Wilson et al. conducted these GWASs and identi fi ed 45 multivariate food liking factors, capturing the genetic architecture of related traits (e.g., fatty food liking, vegetable liking, sweet food liking) that were used in our analyses (Table S1).”
Frailty and Effects of Semaglutide in Obesity-Related HFpEF
Pandey, A., Kitzman, D. W., Chinnakondepalli, K., Patel, S., Borlaug, B. A., Butler, J., Davies, M. J., Shah, S. J., Verma, S., Rönnbäck, C., et al. (2025) · JACC Heart Failure · doi:10.1016/j.jchf.2025.102610 · Cited by 18
GLP-1 Receptor Agonists in Heart Failure
Rahmani, A. R., Dhaliwal, S., Pastena, P., Kazakov, E., Jayaseelan, K., & Kalogeropoulos, A. P. (2025) · Biomolecules · doi:10.3390/biom15101403 · Cited by 19
“%) and received approval for obesity treatment in 2023 [138,139].”
Beyond Weight Loss: Optimizing GLP-1 Receptor Agonist Use in Children
Zaitoon, H., Wauters, A. D., Rodríguez, L. M., & Lynch, J. L. (2025) · Children · doi:10.3390/children12111427 · Cited by 15
“In SURMOUNT 1, Tirzepatide reduced total lean mass by − 10.9% versus − 2.6% with placebo, an estimated treatment difference of − 8.3% (95% CI, − 10.6 to − 6.1) [50].”
InfluentialBarazzoni, R., Sievenpiper, J. L., Genton, L., Kendall, C. W. C., Ballesteros-Pomar, M. D., Giosuè, A., Boirie, Y., Chiavaroli, L., Cederholm, T., Aas, A., et al. (2025) · Clinical Nutrition · doi:10.1016/j.clnu.2025.10.007 · Cited by 19
Incretin-Based Therapies Through the Decades: Molecular Innovations and Clinical Impact
Lee, A. A., Khotina, V. A., Kashirskikh, D. A., Voronko, O. E., Gasanov, V. A. O., & Vasiliev, A. V. (2025) · Medical Sciences · doi:10.3390/medsci13040269 · Cited by 26
Multi-faceted roles of β-arrestins in G protein-coupled receptor endocytosis
Liu, J., Li, X., Ravier, M. A., Eshak, F., Acher, F., Lamy, A., Cimadevila, M., Drube, J., Hoffmann, C., Inoue, A., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-67156-y · Cited by 25
Barana, L., De Fano, M., Cavallo, M., Manco, M., Prete, D., Fanelli, C. G., Porcellati, F., & Pippi, R. (2025) · Nutrients · doi:10.3390/nu18010131 · Cited by 13
“In SURMOUNT-2, participants with obesity and T2DM experienced WL of up to − 14.7% [22].”
InfluentialCastaneda, R., Bechenati, D., Tama, E., Gutiérrez, R. D. J. R., Espinosa, M. A., Villamarin, J. L., Rajjo, T. I., Acosta, A. J., Faubion, S. S., SHUFELT, C. L., et al. (2026) · The Lancet Obstetrics Gynaecology & Women s Health · doi:10.1016/s3050-5038(25)00145-1 · Cited by 17
Effect of Incretin-Based and Nonpharmacologic Weight Loss on Body Composition: A Systematic Review
Batsis, J. A., Gavras, A., Gross, D. C., Cheever, C. R., da Silva, B. R., Filho, L. F. M., Jones, E. P., Batchek, D. J., Khandpekar, S. G., Patel, R., et al. (2026) · Annals of Internal Medicine · doi:10.7326/annals-25-00478 · Cited by 34
The naturally occurring GIP(1-30)NH2 is a GIP receptor agonist in humans
Krogh, L. S. L., Henriksen, K., Stensen, S., Skov‐Jeppesen, K., Bergmann, N. C., Størling, J., ROSENKILDE, M. M., Hartmann, B., Holst, J. J., Gasbjerg, L. S., et al. (2023) · European Journal of Endocrinology · doi:10.1093/ejendo/lvac015 · Cited by 13
Precision nutrition for targeting pathophysiology of cardiometabolic phenotypes
Shannon, C. E., Chathail, M. B. N., Mullin, S. M., Meehan, A., McGillicuddy, F. C., & Roche, H. M. (2023) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-023-09821-5 · Cited by 22
“Notably, many obesity-related complications require >10% weight loss to observe meaningful clinical benefit [4, 5] and, although weight losses of 20-30% may now be obtainable with surgical [6] or pharmacological [7] treatments, intensive lifestyle interventions typically only achieve weight losses of 5-10% [8, 9].”
BackgroundThe potential impact of GLP ‐1 agonists on obstructive sleep apnoea
Hamilton, G. S., & Edwards, B. A. (2023) · Respirology · doi:10.1111/resp.14545 · Cited by 14
“When used for the treatment of obesity, high dose (15 mg) achieved greater than 20% weight loss in 57% of subjects.(8) This magnitude of weight loss is similar to that seen with bariatric surgery.”
BackgroundWeight Loss Interventions for Adults With Obesity-Related Asthma
Foer, D., Forno, E., Holguín, F., & Cahill, K. N. (2023) · The Journal of Allergy and Clinical Immunology In Practice · doi:10.1016/j.jaip.2023.12.041 · Cited by 19
Suicidality among users of glucagon‐like peptide‐1 receptor agonists: An emerging signal?
Lau, D., & Gamble, J. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15459 · Cited by 14
“5,9 These exclusions are common for trials of non-psychiatric medications to minimize losses to follow-up, but nonetheless leave open the possibility that those most likely to experience psychiatric harm from a GLP-1RA are not represented in the efficacy trial populations.”
BackgroundSyndromic and Monogenic Obesity: New Opportunities Due to Genetic-Based Pharmacological Treatment
Kalinderi, K., Goula, V., Sapountzi, E., Tsinopoulou, V. R., & Fidani, L. (2024) · Children · doi:10.3390/children11020153 · Cited by 22
“Interestingly, in a phase III clinical trial, tirzepatide was administered in obese individuals and led to significant weight loss [80,81].”
BackgroundThe effect of bariatric surgery type on cardiac reverse remodelling
Henry, J. A., Abdesselam, I., Deal, O., Lewis, A., Rayner, J. J., Bernard, M., Dutour, A., Gaborit, B., Kober, F., Soghomonian, A., et al. (2024) · International Journal of Obesity · doi:10.1038/s41366-024-01474-x · Cited by 19
“Despite overall reductions in EAT being less than those observed for abdominal VAT, we found an increased ability of RYGB and LSG to decrease EAT relative to LAGB.”
Patil, M., Casari, I., Warne, L. N., & Falasca, M. (2024) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2024.116245 · Cited by 12
Potential Therapeutic Targets in Obesity, Sleep Apnea, Diabetes, and Fatty Liver Disease
Gu, C., Bernstein, N., Mittal, N., Kurnool, S., Schwartz, H. R., Loomba, R. S., & Malhotra, A. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13082231 · Cited by 16
“The phase 3 SURMOUNT-1 trial examined the efficacy of tirzepatide on weight loss against a placebo over the span of 72 weeks [56].”
BackgroundDahir, N. S., Gui, Y., Wu, Y., Sweeney, P., Rouault, A. A. J., Williams, S. Y., Gimenez, L. E., Sawyer, T. K., Joy, S. T., Mapp, A. K., et al. (2024) · Journal of Clinical Investigation · doi:10.1172/jci178250 · Cited by 19
Assessing the state of obesity care: Quality, access, guidelines, and standards
Kaplan, L. M., Apovian, C. M., Ard, J. D., Allison, D. B., Aronne, L. J., Batterham, R. L., Busetto, L., Dicker, D., Horn, D. B., Kelly, A. S., et al. (2024) · Obesity Science & Practice · doi:10.1002/osp4.765 · Cited by 20
Self-citationPatoulias, D., Koufakis, T., Ruža, I., El‐Tanani, M., & Rizzo, M. (2024) · Pragmatic and Observational Research · doi:10.2147/por.s471476 · Cited by 19
“64 At the end of the trial, the percentage change in body weight compared to the baseline was 15% with tirzepatide 5 mg, 19.5% with tirzepatide 10 mg and 20.9% with tirzepatide 15 mg, corresponding to a mean body weight reduction, compared to placebo, of 11.9, 16.4 and 17.8 kg, respectively.”
BackgroundInfluentialRiedinger, C. J., Sakach, J. C., Maples, J. M., Fulton, J., Chippior, J., OʼDonnell, B., O’Malley, D. M., & Chambers, L. (2024) · Gynecologic Oncology · doi:10.1016/j.ygyno.2024.07.008 · Cited by 18
Weight Loss Therapies and Hypertension Benefits
Katsi, V. K., Manta, E., Fragoulis, C., & Tsioufis, K. P. (2024) · Biomedicines · doi:10.3390/biomedicines12102293 · Cited by 17
“Tirzepatide-assisted weight loss in the current trial was associated with statistically greater benefits than a placebo in terms of all assessed cardiovascular risk variables, including SBP and DBP values [60].”
BackgroundManaging obesity in adults with type 1 diabetes
Campos, A., Gutiérrez, R. D. J. R., Galindo, R. J., McCoy, R. G., & Andrade, M. D. H. (2024) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2024.111983 · Cited by 14
Bradley, C. L., McMillin, S. M., Hwang, A. Y., & Sherrill, C. H. (2023) · Annals of Pharmacotherapy · doi:10.1177/10600280221134127 · Cited by 13
Co-agonist therapeutics come of age for obesity
Tan, T. (2022) · Nature Reviews Endocrinology · doi:10.1038/s41574-022-00788-y · Cited by 13
Garcia, M. B., Schadler, K., Chandra, J., Clinton, S. K., Courneya, K. S., Cruz‐Monserrate, Z., Daniel, C. R., Dannenberg, A. J., Demark‐Wahnefried, W., Dewhirst, M. W., et al. (2023) · CA A Cancer Journal for Clinicians · doi:10.3322/caac.21773 · Cited by 17
“recent advances in pharmacologic approaches to induce robust and sustainable weight loss, such as tirzepatide, a novel glucagon‐like peptide‐1 and glucose‐dependent insulinotrophic polypeptide receptor agonist, hold great promise, but these agents have not been well characterized in relation to obesity and cancer.(50)…”
BackgroundAla, M., & Eftekhar, S. P. (2023) · Obesity Reviews · doi:10.1111/obr.13563 · Cited by 15
“1% with placebo.(182) ALA and EFTEKHAR 13 of 21”
BackgroundBiology and Clinical Use of Glucagon-Like Peptide-1 Receptor Agonists in Vascular Protection
Yau, K., Odutayo, A., Dash, S., & Cherney, D. Z. I. (2023) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2023.07.007 · Cited by 22
Distinct Roles for Brain and Pancreas in Basal and Postprandial Glucose Homeostasis
Alonge, K. M., Porte, D., & Schwartz, M. W. (2023) · Diabetes · doi:10.2337/db22-0969 · Cited by 16
Monitoring Report: GLP-1 RA Prescribing Trends - September 2026 DataPreprint
Gratzl, S., Gilbert, K. M., Holler, E., Vachon, M. S., Masters, N. B., Wallen, Z. D., & Cartwright, B. M. G. (2025) · medRxiv · doi:10.1101/2025.03.06.25323524 · Cited by 16
Khawaji, A., A. Jaly, A., A. Bakri, H., Ravi, R., Hattan, A., Khawaji, A., & Najmi, W. (2025) · Journal of Obesity · doi:10.1155/jobe/3442754 · Cited by 13
“In the sixth study, Jastrebof et al. included nondiabetic participants with a BMI of ≥ 30 or ≥ 27 kg/m 2 with comorbidities [32].”
Influential
Metadata
- Authors
- Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., Wharton, S., Connery, L., Alves, B., Kiyosue, A., Zhang, S., Liu, B., Bunck, M. C., & Stefanski, A.
- Affiliations
- Eli Lilly (United States) (US)
- From the Section of Endocrinology and Metabolism, Department of Medicine, and the Section of Pediatric Endocrinology, Department of Pediatrics, Yale University School of Medicine, New Haven, CT (A.M.J.); the Comprehensive Weight Control Center, Division of Endocrinology, Diabetes, and Metabolism, Weill Cornell Medicine, New York (L.J.A.); Eli Lilly, Indianapolis (N.N.A., S.Z., B.L., M.C.B., A.S.); McMaster University, Hamilton, and York University and Wharton Weight Management Clinic, Toronto — all in Ontario, Canada (S.W.); Intend Research, Norman, OK (L.C.); Centro Paulista De Investigação Clínica (Cepic), Sao Paulo (B.A.); and Tokyo-Eki Center-Building Clinic, Tokyo (A.K.).
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2022-07-21
- Volume
- 387
- Issue
- 3
- Pages
- 205-216
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W4281934192
- Semantic Scholar
- 3fb03384cc726ebd9d08c76482e6edf35502d0c7
- Cited by
- 3,838
- References
- 28
- Citations by year
- 2026: 1279 · 2025: 1067 · 2024: 776 · 2023: 562 · 2022: 149
- FWCI
- 382.29
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Eli Lilly and Company
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Life Sciences › Neuroscience › Endocrine and Autonomic Systems › Regulation of Appetite and Obesity
- Keywords
- tirzepatide, obesity, weight loss, GLP-1 receptor agonists, GIP receptor agonist, glucose-dependent insulinotropic polypeptide, glucagon-like peptide-1, dose escalation, body mass index, weight-related comorbidities, treatment discontinuation, treatment-emergent adverse events, drug safety, subcutaneous administration
- MeSH terms
- Tirzepatide, Adult, Dose-Response Relationship, Drug, Double-Blind Method, Glucagon-Like Peptides, Gastric Inhibitory Polypeptide, Humans, Injections, Subcutaneous, Obesity, Weight Loss, Treatment Outcome, Anti-Obesity Agents
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.